Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19

François Danion, Yvon Ruch, Marion Fourtage, Charlotte Kaeuffer, Valentin Greigert, Nicolas Lefebvre, Joris Muller, Thierry Nai, Yves Hansmann
François Danion
aCHU de Strasbourg, Service de Maladies Infectieuses et Tropicales, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yvon Ruch
aCHU de Strasbourg, Service de Maladies Infectieuses et Tropicales, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marion Fourtage
bCHU de Strasbourg, Service Pharmacie-Stérilisation, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte Kaeuffer
aCHU de Strasbourg, Service de Maladies Infectieuses et Tropicales, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valentin Greigert
cCHU de Strasbourg, Service de Médecine Interne, NHC, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Lefebvre
aCHU de Strasbourg, Service de Maladies Infectieuses et Tropicales, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joris Muller
dCHU de Strasbourg, Service de Santé Publique, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thierry Nai
bCHU de Strasbourg, Service Pharmacie-Stérilisation, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Hansmann
aCHU de Strasbourg, Service de Maladies Infectieuses et Tropicales, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01127-20
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

LETTER

The COVID-19 pandemic is an unprecedented situation with physicians awaiting information on therapeutic advances to an extent hardly ever seen in medical history. In the context of this medical crisis, we here exemplify the rapidity by which dissemination of scientific data impacts real-life medical prescriptions.

In Strasbourg University Hospital, France, which was severely affected by the SARS-CoV-2 epidemic at the beginning of March 2020, we analyzed the consumption of antiviral agents according to the emergence of relevant scientific data. At this time, no medically evaluated standard treatment was available, and so, the need for information was vital. The treatment strategies in our center, outside clinical trials, included standard of care alone or in combination with lopinavir-ritonavir or hydroxychloroquine (HCQ) in off-label utilization and without grading of the recommendations. This strategy was in accordance with the French recommendations.

The first patients were treated with standard care alone or in combination with lopinavir-ritonavir (Fig. 1). This treatment had shown some efficacy in nonrandomized trials on SARS-CoV and Middle East respiratory syndrome (1). Moreover, the drug was available, and side effects were known. Data on the first randomized clinical trial appeared online on 18 March and showed no benefit of lopinavir–ritonavir (2). This information triggered a quick decrease in our prescriptions, despite the increase of COVID-19 cases.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Consumption of lopinavir-ritonavir and hydroxychloroquine from 1 March 2020 to 22 April 2020 at Strasbourg University Hospital. The x axis represents the date (month/day, 2020). The left y axis represents the number of patients treated per day by hydroxychloroquine or lopinavir-ritonavir. The right y axis shows the number of patients hospitalized per day with COVID-19. Six patients had been treated by remdesivir (compassionate use). Since 25 March, 102 patients have been included in randomized clinical trials (data not shown). HCQ, hydroxychloroquine; Lopi–rito, lopinavir-ritonavir; Nb, number.

On 20 March, a nonrandomized open-label study on 26 patients treated with hydroxychloroquine (6 patients also received azithromycin) showed some efficacy in decreasing viral load compared with controls (3). This study was widely shared in the French media. On the same day, the president of the United States, Donald Trump, declared that he had a good feeling about this drug. Despite the major limitations of this study—including no outcome data on clinical efficacy or safety, the small number of patients enrolled, and the absence of randomization—we experienced a dramatic increase in our HCQ prescriptions following this publication (Fig. 1). The use of azithromycin had the same trend (data not shown).

In April, HCQ prescriptions decreased for several reasons, including the publication of “negative” studies, the increase in serious adverse events reported, inclusion of some of our patients in clinical trials, and a decrease of new COVID-19 cases (4, 5). Following the publication of a large observational study on 22 May showing no beneficial effect of HCQ, this treatment regimen is not authorized anymore in France outside clinical trials (6). Two weeks later, this article was retracted.

During the emergence of this life-threatening pandemic, developing treatment strategies for COVID-19 is challenging with so little relevant scientifically supported data at hand. Remarkably, we observed that all relevant scientific publications, even if they had important limitations, had rapid and major impacts on the prescription of antivirals. Information flowed quickly, especially when amplified by traditional media, which seems to greatly influence medical prescriptions. Decisively, the results of ongoing randomized clinical trials are urgently needed to define standard treatment as well as novel approaches (7).

ACKNOWLEDGMENTS

F.D. declares personal fees from Gilead outside the submitted work. Y.H. declares personal fees from Gilead and Sanofi outside the submitted work. Y.R., M.F., C.K., N.L., J.M., and T.N. have nothing to declare.

F.D. designed the study and had full access to all of the data. All authors have collected and interpreted the data. F.D. wrote the first draft of the manuscript, and all authors have critically revised the manuscript.

We received no financial support.

  • Copyright © 2020 American Society for Microbiology.

All Rights Reserved.

This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

REFERENCES

  1. 1.↵
    1. Chu CM,
    2. Cheng VCC,
    3. Hung IFN,
    4. Wong MML,
    5. Chan KH,
    6. Chan KS,
    7. Kao RYT,
    8. Poon LLM,
    9. Wong CLP,
    10. Guan Y,
    11. Peiris JSM,
    12. Yuen KY, HKU/UCH SARS Study Group
    . 2004. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59:252–256. doi:10.1136/thorax.2003.012658.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Cao B,
    2. Wang Y,
    3. Wen D,
    4. Liu W,
    5. Wang J,
    6. Fan G,
    7. Ruan L,
    8. Song B,
    9. Cai Y,
    10. Wei M,
    11. Li X,
    12. Xia J,
    13. Chen N,
    14. Xiang J,
    15. Yu T,
    16. Bai T,
    17. Xie X,
    18. Zhang L,
    19. Li C,
    20. Yuan Y,
    21. Chen H,
    22. Li H,
    23. Huang H,
    24. Tu S,
    25. Gong F,
    26. Liu Y,
    27. Wei Y,
    28. Dong C,
    29. Zhou F,
    30. Gu X,
    31. Xu J,
    32. Liu Z,
    33. Zhang Y,
    34. Li H,
    35. Shang L,
    36. Wang K,
    37. Li K,
    38. Zhou X,
    39. Dong X,
    40. Qu Z,
    41. Lu S,
    42. Hu X,
    43. Ruan S,
    44. Luo S,
    45. Wu J,
    46. Peng L,
    47. Cheng F,
    48. Pan L,
    49. Zou J,
    50. Jia C,
    51. Wang J,
    52. Liu X,
    53. Wang S,
    54. Wu X,
    55. Ge Q,
    56. He J,
    57. Zhan H,
    58. Qiu F,
    59. Guo L,
    60. Huang C,
    61. Jaki T,
    62. Hayden FG,
    63. Horby PW,
    64. Zhang D,
    65. Wang C
    . 2020. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382:1787–1799. doi:10.1056/NEJMoa2001282.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Gautret P,
    2. Lagier J-C,
    3. Parola P,
    4. Hoang VT,
    5. Meddeb L,
    6. Mailhe M,
    7. Doudier B,
    8. Courjon J,
    9. Giordanengo V,
    10. Vieira VE,
    11. Dupont HT,
    12. Honoré S,
    13. Colson P,
    14. Chabrière E,
    15. La Scola B,
    16. Rolain J-M,
    17. Brouqui P,
    18. Raoult D
    . 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents doi:10.1016/j.ijantimicag.2020.105949.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Molina JM,
    2. Delaugerre C,
    3. Le Goff J,
    4. Mela-Lima B,
    5. Ponscarme D,
    6. Goldwirt L,
    7. de Castro N
    . 2020. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 50:384. doi:10.1016/j.medmal.2020.03.006.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Borba MGS,
    2. Val FFA,
    3. Sampaio VS,
    4. Alexandre MAA,
    5. Melo GC,
    6. Brito M,
    7. Mourão MPG,
    8. Brito-Sousa JD,
    9. Baía-da-Silva D,
    10. Guerra MVF,
    11. Hajjar LA,
    12. Pinto RC,
    13. Balieiro AAS,
    14. Pacheco AGF,
    15. Santos JDO,
    16. Naveca FG,
    17. Xavier MS,
    18. Siqueira AM,
    19. Schwarzbold A,
    20. Croda J,
    21. Nogueira ML,
    22. Romero GAS,
    23. Bassat Q,
    24. Fontes CJ,
    25. Albuquerque BC,
    26. Daniel-Ribeiro C-T,
    27. Monteiro WM,
    28. Lacerda M, CloroCovid-19 Team
    . 2020. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 3:e208857. doi:10.1001/jamanetworkopen.2020.8857.
    OpenUrlCrossRef
  6. 6.↵
    1. Mehra MR,
    2. Desai SS,
    3. Ruschitzka F,
    4. Patel AN
    . 2020. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet doi:10.1016/S0140-6736(20)31180-6. [Retraction, https://doi.org/10.1016/S0140-6736(20)31324-6.]
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Li H,
    2. Zhou Y,
    3. Zhang M,
    4. Wang H,
    5. Zhao Q,
    6. Liu J
    . 2020. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother 64:e00483-20. doi:10.1128/AAC.00483-20.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19
François Danion, Yvon Ruch, Marion Fourtage, Charlotte Kaeuffer, Valentin Greigert, Nicolas Lefebvre, Joris Muller, Thierry Nai, Yves Hansmann
Antimicrobial Agents and Chemotherapy Jul 2020, 64 (8) e01127-20; DOI: 10.1128/AAC.01127-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19
François Danion, Yvon Ruch, Marion Fourtage, Charlotte Kaeuffer, Valentin Greigert, Nicolas Lefebvre, Joris Muller, Thierry Nai, Yves Hansmann
Antimicrobial Agents and Chemotherapy Jul 2020, 64 (8) e01127-20; DOI: 10.1128/AAC.01127-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Hydroxychloroquine
lopinavir–ritonavir
COVID-19
consumption
treatment

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596